Question 1

What does GLP-1 stand for?

Accepted Answer

GLP-1 stands for glucagon-like peptide-1, a hormone the gut releases after a meal. A GLP-1 receptor agonist is a manufactured molecule that switches on the same receptor for far longer than the natural hormone lasts. That is the whole idea behind the class. A 2025 review states that these agonists have become central in managing obesity and type 2 diabetes, mainly through appetite suppression and metabolic regulation. A 2020 review puts the measured effects in order, reporting that GLP-1 receptor agonists improve glucose balance, reduce bodyweight, and over time benefit cardiovascular health in type 2 diabetes. So the name describes a receptor rather than a purpose. What any single member of the class was measured to do depends on the trials that were run on that molecule, which is why the numbers further down name a compound every time.

Question 2

Which medicines count as a GLP-1?

Accepted Answer

More than most people expect, and they are not interchangeable. The seven cardiovascular outcome trials pooled in a 2019 analysis covered lixisenatide, liraglutide, semaglutide, exenatide, albiglutide, dulaglutide and oral semaglutide. That is six injected or swallowed peptides and one tablet form of a peptide already on the list. Two newer kinds sit at the edges. Tirzepatide is described by its own pharmacology work as a dual GIP and GLP-1 receptor agonist, and that analysis found it engages the GIP receptor more strongly than the GLP-1 receptor. Orforglipron is a small-molecule, non-peptide oral GLP-1 receptor agonist being investigated for obesity, which means it is not a peptide at all. Read the label on the category. A dual agonist and a small molecule both act on the GLP-1 receptor, yet neither is the same thing as the older injected peptides, and trial results do not transfer between them.

Question 3

What does a GLP-1 do in your body?

Accepted Answer

Two things at once, in two places. Centrally, the 2025 mechanism review reports that these agonists act on brain regions controlling appetite, influencing the release of signalling molecules that regulate hunger and energy expenditure. Peripherally, the same review describes how they improve glucose control by enhancing insulin secretion, reducing glucagon release, delaying gastric emptying and regulating gut hormones. Glucagon is the hormone that pushes blood sugar up, and delayed gastric emptying means food sits in the stomach longer. The review adds that they also reduce triglycerides and low-density lipoprotein cholesterol in the people studied. The appetite arm shows up in what people eat. A 2024 narrative review of dietary intake on these medicines found that total calorie intake was reduced by 16 to 39 per cent among the patients studied. That is the behavioural half of the result, and it is the half a reader can actually observe.

Question 4

How much weight did people lose?

Accepted Answer

At the class level, the honest figure is smaller than the headline figure. A 2025 pooled analysis of 22 randomised trials in 2,258 participants found that GLP-1 receptor agonists significantly reduced total body weight, by an average of about 3.5 kilograms against comparison groups. That average covers older and newer molecules together, at a range of amounts, in trials of different lengths. The single-compound numbers are much larger, and they sit on the page for each compound rather than in a class average. Outside trials the figure shrinks again. The 2025 real-world review reports that weight reduction in clinical practice tends to be lower than in randomised controlled trials, while outcomes approach those seen in trials among highly adherent patients. Two readings of the same medicines, and the difference between them is mostly whether people kept taking them.

Question 5

Across the class, is the lost weight fat or muscle?

Accepted Answer

Both, in a ratio the same 2025 pooled analysis measured directly. Across 22 randomised trials it found reductions in fat mass of about 3 kilograms and in lean mass of about 0.9 kilograms, with lean mass loss making up roughly a quarter of the total weight lost. The same analysis records that relative lean mass, measured as a percentage change from where people started, was unaffected. It also separates the molecules, reporting that liraglutide was the only GLP-1 receptor agonist to achieve significant weight reduction without significantly reducing lean mass in these participants. Research is already chasing that gap. In diet-induced obese mice, combining an antibody against the activin type II receptor with semaglutide produced greater fat loss while preserving lean mass. Activin type II receptors are muscle growth brakes, and that work is in mice rather than in people, so it marks a direction rather than a result.

Question 6

What is the strongest GLP-1 for weight loss?

Accepted Answer

The comparison exists, and it is narrower than the question implies. A 2026 pooled analysis of randomised trials found that all tirzepatide amounts were associated with statistically greater improvements in weight reduction than liraglutide, and the two higher amounts also beat semaglutide. Three cautions come with that. The analysis kept only six of the 42 trials it screened after assessing how comparable they were. Tirzepatide is a dual GIP and GLP-1 receptor agonist rather than a selective GLP-1 receptor agonist, so the comparison crosses a line in the pharmacology. And a 2024 pooled analysis of 28 trials in people with type 2 diabetes found the same direction on weight, which makes the finding consistent rather than decisive. A trial average is not a forecast for one person. We are not ranking this class, and the per-compound results belong on the page for each compound.

Question 7

What did they do for blood sugar?

Accepted Answer

This is the outcome the class was built for, and it is the best documented thing it does. HbA1c is the standard measure, an average of blood sugar over roughly three months. Two trials show the range. In adults with early type 2 diabetes, a phase 3 trial in 559 participants found that oral orforglipron significantly reduced HbA1c over 40 weeks. In the PIONEER 1 trial, oral semaglutide alone produced superior and clinically relevant improvements in HbA1c at every amount tested, against placebo, in patients managed by diet and exercise. The newer dual agonists moved the ceiling again. A 2022 review of diabetes medicines reports that data from dual agonists, in particular tirzepatide, show unprecedented reductions in HbA1c, body weight and cardiovascular risk factors. That phrasing is the review's own, and it describes a comparison against earlier medicines rather than against no medicine at all.

Question 8

What did they do for the heart and the kidneys?

Accepted Answer

This is the strongest class-wide evidence that exists, because it was measured across seven separate trials rather than one. The 2019 pooled analysis of 56 004 participants found that GLP-1 receptor agonist treatment reduced major adverse cardiovascular events by 12 per cent. Those events are death from heart disease, stroke and heart attack, counted together as one outcome. Its conclusion is written at class level: treatment with GLP-1 receptor agonists has beneficial effects on cardiovascular, mortality and kidney outcomes in patients with type 2 diabetes. A 2024 review agrees that the outcome trials in patients with diabetes and obesity confirmed fewer heart deaths, and lower rates of heart attack and of stroke. It also notes that nobody has fully worked out why. The kidney signal travels with it. A 2017 review reports that GLP-1 receptor agonists and a second class of diabetes medicine both reduced protein leaking into the urine, and slowed the time to kidney failure in patients.

Question 9

What else are they being studied for?

Accepted Answer

Quite a lot, though almost all of it is a single-molecule programme rather than a class result. A 2025 review of semaglutide lists where the work has spread: fatty liver disease, heart failure, polycystic ovary syndrome, obstructive sleep apnea, alcohol use disorder and Alzheimer's disease. Sleep apnea is the one people ask about most often after weight. It appears on that list as an emerging area, which is a careful way of saying the evidence is being gathered rather than settled. The same review notes that ongoing studies such as the FOCUS trial are investigating effects on the small blood vessels damaged by diabetes. Liver disease has gone furthest. A phase 2 trial in adults already taking a GLP-1 receptor agonist concluded that liver health in those patients may be further improved by adding an experimental liver compound. That is a trial about a combination rather than about the GLP-1 alone.

Question 10

Do the pills work as well as the injections?

Accepted Answer

On the published record the oral members of this class produce real results, and the comparison that would settle the question has not been run. Oral semaglutide came first. The PIONEER 1 trial compared the first oral GLP-1 receptor agonist against placebo in patients with type 2 diabetes managed by diet and exercise alone. Then came the small molecules. In a phase 2 trial, mean weight change at week 36 ranged from -9.4 per cent to -14.7 per cent with orforglipron, against -2.3 per cent with placebo. A phase 3 trial confirmed the direction, finding that 72 weeks of orforglipron led to significantly greater reductions in body weight than placebo in adults with obesity. None of those trials put a pill against an injection directly, so what exists is two sets of placebo comparisons rather than a head-to-head answer.

Question 11

How many weeks of use do these figures represent?

Accepted Answer

Longer than most people expect, and that matters for reading any result from this class. The phase 2 orforglipron trial measured its main weight endpoint at week 26 and a second one at week 36. The phase 3 trial of the same compound ran for 72 weeks alongside diet and physical activity, with 3,127 patients randomised into it. The exercise trials in this class ran a year of randomised treatment after an eight-week diet. So the published figures are end-of-trial figures, measured after months of continuous treatment at an amount reached by gradual escalation. A percentage at week 72 does not describe week six, and nothing in this research measures what one individual experiences in a particular month. That is the most common misreading of these numbers.

Question 12

Does exercise change what a GLP-1 does?

Accepted Answer

It changes what the weight loss is made of, and this is the best-studied pairing in the class. A randomised trial put 195 adults with obesity through an eight-week diet. It then assigned them to placebo, to supervised exercise, to liraglutide, or to exercise and liraglutide together for a year. The combination did more than either part alone. The trial reports that exercise with liraglutide reduced metabolic syndrome severity, belly fat and inflammation, and may therefore lower heart and metabolic risk more than each one by itself. Fitness split the arms more sharply still. A later analysis found that exercise alone led to similar benefits in physical fitness, whereas liraglutide alone did not improve it. Read those two findings together. The medicine moved the weight and the blood markers, while the exercise moved what the participants could do with their bodies.

Question 13

Do you gain weight after stopping a GLP-1?

Accepted Answer

The weight comes back, and one trial measured how much. Its authors state the general case first: termination of obesity medication results in weight regain towards pre-treatment body weight. Then the measurement. In the year after treatment ended, weight regain was 6.0 kilograms larger after stopping liraglutide than after stopping supervised exercise, in the same randomised population. The participants who had trained kept more of what they had lost than the participants who had only taken the medicine. This is why the discontinuation figures matter to a benefits page at all. The 2025 real-world review lists studies of the effects of stopping treatment among the research this class still needs. A result measured while people are taking something is a result about taking it, which is a different question from what they keep afterwards.

Question 14

Did they work in young people?

Accepted Answer

One trial in this class has reported in young people, and it measured blood sugar rather than weight. It randomly assigned 99 participants with youth-onset type 2 diabetes, with a mean age of 14.7 years, to tirzepatide or to placebo. The double-blind phase ran over 30 weeks, followed by an open-label extension for 22 weeks in which all participants received tirzepatide. The trial reports that tirzepatide produced significant improvements in blood sugar control and body mass index against placebo, and that those effects were sustained over one year. Its own framing explains why the trial was run. Treatment options for youth-onset type 2 diabetes are limited and have shown lower effect on blood sugar than the options for adults. That is one trial, in one condition, with one molecule, and it is the entire paediatric record behind this page.

Question 15

What has not been measured across the class?

Accepted Answer

Three things, each named by the research that went looking. The first is muscle over time. The 2025 body-composition analysis opens by saying that the impact of these medicines on lean mass remains uncertain, and its pooled trials measured that in weeks and months. The second is what to eat alongside one. The 2024 dietary review found that few studies evaluated the actual composition of the diet, which leaves the most practical daily question largely unstudied. The third is whether the newest molecules carry the older ones' heart record. A trial protocol published in 2024 states that the cardiovascular safety and efficacy of tirzepatide have not been definitively assessed in a cardiovascular outcomes trial, which is why 13,299 people were randomised into one. Until it reports, the class heart evidence belongs to the medicines that finished their own outcome trials rather than to every molecule acting on this receptor.

GLP-1: what the research measured